SK5102002A3 - Oral formulations for anti-tumor compounds - Google Patents

Oral formulations for anti-tumor compounds Download PDF

Info

Publication number: SK5102002A3
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; pharmaceutically acceptable; lecithin; cpt; composition according
Prior art date: 1999-10-22

Application number

SK510-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Lorena Muggetti

Alessandro Martini

Paola Civaroli

Christopher James

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-22

Filing date

2000-10-02

Publication date

2002-11-06

2000-10-02 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2002-11-06 Publication of SK5102002A3 publication Critical patent/SK5102002A3/sk

Links

239000000203 mixture Substances 0.000 title claims description 39
230000000259 anti-tumor effect Effects 0.000 title claims description 5
238000009472 formulation Methods 0.000 title description 25
150000001875 compounds Chemical class 0.000 title 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims abstract description 32
125000005456 glyceride group Chemical group 0.000 claims abstract description 25
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
238000011049 filling Methods 0.000 claims abstract description 11
239000003937 drug carrier Substances 0.000 claims abstract description 3
239000002775 capsule Substances 0.000 claims description 52
238000002360 preparation method Methods 0.000 claims description 27
239000008194 pharmaceutical composition Substances 0.000 claims description 23
239000000787 lecithin Substances 0.000 claims description 19
235000010445 lecithin Nutrition 0.000 claims description 19
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 16
229940067606 lecithin Drugs 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 12
229920001223 polyethylene glycol Polymers 0.000 claims description 12
238000000034 method Methods 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 11
239000006185 dispersion Substances 0.000 claims description 10
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 9
239000002202 Polyethylene glycol Substances 0.000 claims description 8
229940127093 camptothecin Drugs 0.000 claims description 8
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical group C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 8
150000003904 phospholipids Chemical class 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
-1 thalidomide Natural products 0.000 claims description 8
201000011510 cancer Diseases 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
239000003921 oil Substances 0.000 claims description 7
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 6
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 6
239000008347 soybean phospholipid Substances 0.000 claims description 6
229960002190 topotecan hydrochloride Drugs 0.000 claims description 6
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 4
FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
239000008240 homogeneous mixture Substances 0.000 claims description 4
230000001737 promoting effect Effects 0.000 claims description 4
238000010521 absorption reaction Methods 0.000 claims description 3
229940088679 drug related substance Drugs 0.000 claims description 3
230000002708 enhancing effect Effects 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
239000004094 surface-active agent Substances 0.000 claims description 3
239000004034 viscosity adjusting agent Substances 0.000 claims description 3
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
MYQKIWCVEPUPIL-QFIPXVFZSA-N 7-ethylcamptothecin Chemical compound C1=CC=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 MYQKIWCVEPUPIL-QFIPXVFZSA-N 0.000 claims description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
102000001301 EGF receptor Human genes 0.000 claims description 2
108060006698 EGF receptor Proteins 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
108010016076 Octreotide Proteins 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
229940123237 Taxane Drugs 0.000 claims description 2
229930013930 alkaloid Natural products 0.000 claims description 2
229940100198 alkylating agent Drugs 0.000 claims description 2
239000002168 alkylating agent Substances 0.000 claims description 2
239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000000340 anti-metabolite Effects 0.000 claims description 2
230000001946 anti-microtubular Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
229940100197 antimetabolite Drugs 0.000 claims description 2
239000002256 antimetabolite Substances 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000003886 aromatase inhibitor Substances 0.000 claims description 2
229940046844 aromatase inhibitors Drugs 0.000 claims description 2
229960004117 capecitabine Drugs 0.000 claims description 2
229960004562 carboplatin Drugs 0.000 claims description 2
229960000590 celecoxib Drugs 0.000 claims description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
239000008139 complexing agent Substances 0.000 claims description 2
239000002270 dispersing agent Substances 0.000 claims description 2
229960003668 docetaxel Drugs 0.000 claims description 2
229960004750 estramustine phosphate Drugs 0.000 claims description 2
ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 claims description 2
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
235000008191 folinic acid Nutrition 0.000 claims description 2
239000011672 folinic acid Substances 0.000 claims description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
229940125697 hormonal agent Drugs 0.000 claims description 2
229960001691 leucovorin Drugs 0.000 claims description 2
229960002700 octreotide Drugs 0.000 claims description 2
229960001756 oxaliplatin Drugs 0.000 claims description 2
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
229960004662 parecoxib Drugs 0.000 claims description 2
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims description 2
150000003057 platinum Chemical class 0.000 claims description 2
229960000371 rofecoxib Drugs 0.000 claims description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
229960003433 thalidomide Drugs 0.000 claims description 2
239000003734 thymidylate synthase inhibitor Substances 0.000 claims description 2
229960002004 valdecoxib Drugs 0.000 claims description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims description 2
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims 1
230000003078 antioxidant effect Effects 0.000 claims 1
190000008236 carboplatin Chemical compound 0.000 claims 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
239000007787 solid Substances 0.000 abstract description 38
239000011159 matrix material Substances 0.000 abstract 1
GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 40
239000000945 filler Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 13
238000003756 stirring Methods 0.000 description 9
238000000280 densification Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000013543 active substance Substances 0.000 description 6
230000032683 aging Effects 0.000 description 6
238000003860 storage Methods 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
238000002156 mixing Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000003826 tablet Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
238000009826 distribution Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000003760 magnetic stirring Methods 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920000223 polyglycerol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000008719 thickening Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000003915 DNA Topoisomerases Human genes 0.000 description 2
108090000323 DNA Topoisomerases Proteins 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
208000015634 Rectal Neoplasms Diseases 0.000 description 2
230000018199 S phase Effects 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
229960004768 irinotecan Drugs 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
238000013112 stability test Methods 0.000 description 2
229960000303 topotecan Drugs 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
238000005429 filling process Methods 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000011396 initial chemotherapy Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000006207 intravenous dosage form Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
239000008184 oral solid dosage form Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000003346 palm kernel oil Substances 0.000 description 1
235000019865 palm kernel oil Nutrition 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
229950009213 rubitecan Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000013269 sustained drug release Methods 0.000 description 1
229920001169 thermoplastic Polymers 0.000 description 1
239000004416 thermosoftening plastic Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
235000020138 yakult Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK510-2002A 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds SK5102002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9925127.4A GB9925127D0 (en)	1999-10-22	1999-10-22	Oral formulations for anti-tumor compounds
PCT/EP2000/009647 WO2001030351A1 (en)	1999-10-22	2000-10-02	Oral formulations for anti-tumor compounds

Publications (1)

Publication Number	Publication Date
SK5102002A3 true SK5102002A3 (en)	2002-11-06

Family

ID=10863264

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK510-2002A SK5102002A3 (en)	1999-10-22	2000-10-02	Oral formulations for anti-tumor compounds

Country Status (26)

Country	Link
US (1)	US7201913B1 (cs)
EP (1)	EP1223936A1 (cs)
JP (1)	JP2003512430A (cs)
KR (1)	KR100838097B1 (cs)
CN (1)	CN1198616C (cs)
AR (1)	AR031834A1 (cs)
AU (1)	AU784201B2 (cs)
BR (1)	BR0014902A (cs)
CA (1)	CA2387648A1 (cs)
CO (1)	CO5251471A1 (cs)
CZ (1)	CZ20021372A3 (cs)
EA (1)	EA008284B1 (cs)
GB (1)	GB9925127D0 (cs)
HK (1)	HK1048253B (cs)
HU (1)	HUP0202850A3 (cs)
IL (2)	IL149044A0 (cs)
MX (1)	MXPA02003904A (cs)
MY (1)	MY138106A (cs)
NO (1)	NO322782B1 (cs)
NZ (1)	NZ518398A (cs)
PE (1)	PE20010809A1 (cs)
PL (1)	PL356236A1 (cs)
SK (1)	SK5102002A3 (cs)
TW (1)	TWI233355B (cs)
WO (1)	WO2001030351A1 (cs)
ZA (1)	ZA200203042B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2401191C (en)	2000-02-28	2006-05-02	Aventis Pharma S.A.	A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
ITRM20030074A1 (it) *	2003-02-21	2004-08-22	Pharmacia Italia Spa	Formulazioni semisolide a rilascio immediato intese
US7871632B2 (en)	2004-07-12	2011-01-18	Adventrx Pharmaceuticals, Inc.	Compositions for delivering highly water soluble drugs
GT200500310A (es)	2004-11-19	2006-06-19		Compuestos organicos
SA06270147B1 (ar)	2005-06-09	2009-12-22	نوفارتيس ايه جي	عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US20070053869A1 (en) *	2005-09-02	2007-03-08	Yuichi Sugiyama	Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
JP5297815B2 (ja) *	2007-01-26	2013-09-25	株式会社ポーラファルマ	医薬組成物
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100310661A1 (en) *	2007-07-16	2010-12-09	Poniard Pharmaceuticals, Inc.	Oral formulations for picoplatin
CA2715348A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
HUP0900614A2 (en) *	2009-09-29	2011-05-30	Mate Dr Hidvegi	Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production
US20120322752A1 (en) *	2009-12-08	2012-12-20	Sung Kyun Lee	SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
MX2015010041A (es)	2013-02-05	2015-10-30	Purdue Pharma Lp	Formulacion farmaceuticas resistentes a la alteracion.
JP6704345B2 (ja) *	2014-01-17	2020-06-03	オンコラルファーマエーピーエス	癌治療のためのイリノテカンの固体経口剤形
CN110448533B (zh) *	2014-12-05	2022-03-29	天津键凯科技有限公司	一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法
KR102293907B1 (ko)	2015-06-30	2021-08-26	한미약품 주식회사	이리노테칸 함유 경구용 고형제제 및 그 제조방법
TWI795381B (zh)	2016-12-21	2023-03-11	比利時商健生藥品公司	作為ｍａｌｔ１抑制劑之吡唑衍生物
KR102066402B1 (ko) *	2017-12-22	2020-01-15	대화제약 주식회사	이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
EP3953345B1 (en)	2019-04-11	2023-04-05	Janssen Pharmaceutica NV	Pyridine rings containing derivatives as malt1 inhibitors
KR102185475B1 (ko)	2019-06-20	2020-12-02	대화제약 주식회사	이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA909847B (en) *	1989-12-13	1992-08-26	Lilly Co Eli	Glycopeptide derivatives
US5552156A (en)	1992-10-23	1996-09-03	Ohio State University	Liposomal and micellular stabilization of camptothecin drugs
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5433951A (en)	1993-10-13	1995-07-18	Bristol-Myers Squibb Company	Sustained release formulation containing captopril and method
IL115099A (en)	1994-10-14	1999-04-11	Upjohn Co	Lyophilizate of phospholipid complex of water insoluble camptothecins
IL116674A (en) *	1995-01-09	2003-05-29	Mendell Co Inc Edward	Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5954998A (en) *	1995-05-25	1999-09-21	The Clorox Company	Liquid peracid precursor colloidal dispersions: oil-core vesicles
AU743024B2 (en) *	1997-03-05	2002-01-17	Sugen, Inc.	Formulations for hydrophobic pharmaceutical agents
GB9711962D0 (en) *	1997-06-10	1997-08-06	Reckitt & Colmann Prod Ltd	Therapeutically active compositions
PL192080B1 (pl) *	1997-07-29	2006-08-31	Upjohn Co	Kompozycja farmaceutyczna zawierająca związek piranonowy
AR013261A1 (es)	1997-08-01	2000-12-13	Smithkline Beecham Corp	Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
FR2775188B1 (fr)	1998-02-23	2001-03-09	Lipha	Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
CA2373931A1 (en) *	1999-05-17	2000-11-23	Richard Love	Dfmo and celecoxib in combination for cancer chemoprevention and therapy
GB9918885D0 (en) *	1999-08-10	1999-10-13	Pharmacia & Upjohn Spa	Pharmaceutical formulations in hydroxypropymethycellulose capsules

1999
- 1999-10-22 GB GBGB9925127.4A patent/GB9925127D0/en not_active Ceased
2000
- 2000-10-02 CN CNB008146594A patent/CN1198616C/zh not_active Expired - Fee Related
- 2000-10-02 PL PL00356236A patent/PL356236A1/xx not_active IP Right Cessation
- 2000-10-02 WO PCT/EP2000/009647 patent/WO2001030351A1/en not_active Ceased
- 2000-10-02 US US10/110,225 patent/US7201913B1/en not_active Expired - Fee Related
- 2000-10-02 JP JP2001532771A patent/JP2003512430A/ja not_active Withdrawn
- 2000-10-02 HK HK03100370.7A patent/HK1048253B/zh not_active IP Right Cessation
- 2000-10-02 AU AU76613/00A patent/AU784201B2/en not_active Ceased
- 2000-10-02 IL IL14904400A patent/IL149044A0/xx active IP Right Grant
- 2000-10-02 MX MXPA02003904A patent/MXPA02003904A/es active IP Right Grant
- 2000-10-02 EP EP00966102A patent/EP1223936A1/en not_active Withdrawn
- 2000-10-02 CZ CZ20021372A patent/CZ20021372A3/cs unknown
- 2000-10-02 KR KR1020027005068A patent/KR100838097B1/ko not_active Expired - Fee Related
- 2000-10-02 SK SK510-2002A patent/SK5102002A3/sk unknown
- 2000-10-02 HU HU0202850A patent/HUP0202850A3/hu unknown
- 2000-10-02 NZ NZ518398A patent/NZ518398A/en unknown
- 2000-10-02 CA CA002387648A patent/CA2387648A1/en not_active Abandoned
- 2000-10-02 EA EA200200480A patent/EA008284B1/ru not_active IP Right Cessation
- 2000-10-02 BR BR0014902-0A patent/BR0014902A/pt not_active Application Discontinuation
- 2000-10-07 TW TW089121016A patent/TWI233355B/zh not_active IP Right Cessation
- 2000-10-19 MY MYPI20004934A patent/MY138106A/en unknown
- 2000-10-19 AR ARP000105495A patent/AR031834A1/es unknown
- 2000-10-19 PE PE2000001113A patent/PE20010809A1/es not_active Application Discontinuation
- 2000-10-19 CO CO00079673A patent/CO5251471A1/es not_active Application Discontinuation
2002
- 2002-04-09 IL IL149044A patent/IL149044A/en not_active IP Right Cessation
- 2002-04-17 ZA ZA200203042A patent/ZA200203042B/en unknown
- 2002-04-18 NO NO20021834A patent/NO322782B1/no unknown

Also Published As

Publication number	Publication date
KR100838097B1 (ko)	2008-06-13
MXPA02003904A (es)	2003-07-14
PE20010809A1 (es)	2001-08-01
HK1048253B (zh)	2005-12-02
HUP0202850A3 (en)	2004-12-28
KR20020045613A (ko)	2002-06-19
NO322782B1 (no)	2006-12-11
BR0014902A (pt)	2002-06-11
AU7661300A (en)	2001-05-08
NZ518398A (en)	2004-01-30
HUP0202850A2 (hu)	2003-01-28
CZ20021372A3 (cs)	2002-09-11
IL149044A (en)	2007-03-08
IL149044A0 (en)	2002-11-10
AU784201B2 (en)	2006-02-23
CN1382050A (zh)	2002-11-27
PL356236A1 (en)	2004-06-28
CA2387648A1 (en)	2001-05-03
WO2001030351A1 (en)	2001-05-03
NO20021834D0 (no)	2002-04-18
CO5251471A1 (es)	2003-02-28
MY138106A (en)	2009-04-30
EA008284B1 (ru)	2007-04-27
CN1198616C (zh)	2005-04-27
US7201913B1 (en)	2007-04-10
ZA200203042B (en)	2003-04-17
GB9925127D0 (en)	1999-12-22
HK1048253A1 (en)	2003-03-28
AR031834A1 (es)	2003-10-08
TWI233355B (en)	2005-06-01
NO20021834L (no)	2002-04-18
EA200200480A1 (ru)	2002-10-31
EP1223936A1 (en)	2002-07-24
JP2003512430A (ja)	2003-04-02

Publication	Publication Date	Title
SK5102002A3 (en)	2002-11-06	Oral formulations for anti-tumor compounds
AU762926B2 (en)	2003-07-10	Methods and compositions for delivery of taxanes
EA006550B1 (ru)	2006-02-24	Фармацевтическая композиция на основе микронизированного прогестерона, способ её получения и её применение
CA2354039C (en)	2008-09-23	Pharmaceutical formulations in hydroxypropylmethylcellulose capsules
CN101601642A (zh)	2009-12-16	一种囊泡类给药系统及其应用
EP1915153A2 (en)	2008-04-30	Immediate release therapeutic systems for improved oral absorption of 7-[(e)-tert-butyloxyiminomethyl]camtothecin
EP4140480A1 (en)	2023-03-01	Drug combination and use thereof
KR20240100433A (ko)	2024-07-01	암의 치료에 유용한 면역원성 세포 사멸 (icd) 유도 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 나노담체 조성물 및 그의 방법
PL206522B1 (pl)	2010-08-31	Kompozycja farmaceutyczna zawierająca winorelbinę w miękkich kapsułkach i jej zastosowanie
CN107510652B (zh)	2018-07-13	用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN108066311B (zh)	2020-09-08	一种吉马替康胶囊及其制备方法
RU2857128C2 (ru)	2026-02-25	Суппозитории ректальные и вагинальные на основе индол-3-карбинола и способ их получения
JP7492977B2 (ja)	2024-05-30	イリノテカン遊離塩基を含む経口投与用の医薬組成物
WO2022204757A1 (en)	2022-10-06	Improved isoflavone formulation
KR20240053626A (ko)	2024-04-24	강화된 sn-38 용해성 및 경구 흡수성을 갖는 제형
US20060094692A1 (en)	2006-05-04	Pharmaceutical formulations of camptothecins and process for making same